SureNano Science’s GLP-1 Triple Agonist GEP-44 Targets Obesity Market as Next-Generation Therapies Gain Traction
SureNano Science Ltd. is highlighted in a BioMedWire editorial for its subsidiary GlucaPharm’s GEP-44 triple agonist peptide, which aims to improve efficacy, tolerability, and delivery flexibility in the growing GLP-1 market for obesity and metabolic diseases.
